{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:34:40Z","timestamp":1788021280598,"version":"build-2784847793"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,29]]},"DOI":"10.7759\/cureus.83216","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:38:57Z","timestamp":1745973537000},"source":"Crossref","is-referenced-by-count":1,"title":["Mismatch Repair-Deficient FIGO Stage IA Endometrial Adenocarcinoma With Negative Nodal Biopsy Presenting as Isolated Orbital Metastasis"],"prefix":"10.7759","author":[{"given":"Steven B","family":"Barker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravanti","family":"Macherla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Surveillance, Epidemiology, and End Results (SEER) program. Cancer of the endometrium - cancer stat facts. Accessed. July 5, 2023: https:\/\/seer.cancer.gov\/statfacts\/html\/corp.html."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial cancer","volume":"387","author":"Morice P","year":"2016","unstructured":"Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016, 387:1094-108. 10.1016\/S0140-6736(15)00130-0","journal-title":"Lancet"},{"key":"ref3","article-title":"Endometrial carcinoma: epidemiology, risk factors, and prevention","author":"Chen LM","year":"2023","unstructured":"Chen LM, Berek JS. Endometrial carcinoma: epidemiology, risk factors, and prevention. UpToDate. Ted. W. Post (ed): UpToDate, Waltham, MA; 2023."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000001119","article-title":"Endometrial cancer in the elderly: does age influence surgical treatments, outcomes, and prognosis?","volume":"25","author":"Koual M","year":"2018","unstructured":"Koual M, Ngo C, Girault A, L\u00e9curu F, Bats AS. Endometrial cancer in the elderly: does age influence surgical treatments, outcomes, and prognosis?. Menopause. 2018, 25:968-76. 10.1097\/GME.0000000000001119","journal-title":"Menopause"},{"key":"ref5","article-title":"Endometrial cancer","author":"Mahdy H","year":"2023","unstructured":"Mahdy H, Vadakekut ES, Crotzer D. Endometrial cancer. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref6","article-title":"","author":"Chi DS","year":"2017","unstructured":"Chi DS, Berchuck A, Dizon DS, Yashar CM. Principles and Practice of Gynecologic Oncology. Lippincott Williams & Wilkins, Philadelphia, PA; 2017. https:\/\/oncology.lwwhealthlibrary.com\/book.aspx?bookid=2054."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.2596","article-title":"Type I and II endometrial cancers: have they different risk factors?","volume":"31","author":"Setiawan VW","year":"2013","unstructured":"Setiawan VW, Yang HP, Pike MC, et al.. Type I and II endometrial cancers: have they different risk factors?. J Clin Oncol. 2013, 31:2607-18. 10.1200\/JCO.2012.48.2596","journal-title":"J Clin Oncol"},{"key":"ref8","unstructured":"Endometrial carcinoma. serous and clear cell histologies. (2023). Accessed: July 5, 2023: https:\/\/www.uptodate.com\/contents\/endometrial-carcinoma-serous-and-clear-cell-histologies."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000462977.61229.de","article-title":"Practice Bulletin No. 149: endometrial cancer","volume":"125","year":"2015","unstructured":"Practice Bulletin No. 149. endometrial cancer. Obstet Gynecol. 2015, 125:1006-26. 10.1097\/01.AOG.0000462977.61229.de","journal-title":"Obstet Gynecol"},{"key":"ref10","unstructured":"Endometrial carcinoma. clinical features, diagnosis, prognosis, and screening. (2023). Accessed: July 5, 2023: https:\/\/www.uptodate.com\/contents\/endometrial-carcinoma-clinical-features-diagnosis-prognosis-and-screening."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth C","year":"2013","unstructured":"Kandoth C, Schultz N, Cherniack AD, et al.. Integrated genomic characterization of endometrial carcinoma. Nature. 2013, 497:67-73. 10.1038\/nature12113","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacr.2020.09.001","article-title":"ACR Appropriateness Criteria\u00ae pretreatment evaluation and follow-up of endometrial cancer","volume":"17","author":"Reinhold C","year":"2020","unstructured":"Reinhold C, Ueno Y, Akin EA, et al.. ACR Appropriateness Criteria\u00ae pretreatment evaluation and follow-up of endometrial cancer. J Am Coll Radiol. 2020, 17:S472-86. 10.1016\/j.jacr.2020.09.001","journal-title":"J Am Coll Radiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2003.11.048","article-title":"A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study","volume":"92","author":"Keys HM","year":"2004","unstructured":"Keys HM, Roberts JA, Brunetto VL, et al.. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004, 92:744-51. 10.1016\/j.ygyno.2003.11.048","journal-title":"Gynecol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.03.007","article-title":"Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review","volume":"63","author":"Scholten AN","year":"2005","unstructured":"Scholten AN, van Putten WL, Beerman H, et al.. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005, 63:834-8. 10.1016\/j.ijrobp.2005.03.007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12112834","article-title":"Serum CA125 and HE4 as biomarkers for the detection of endometrial cancer and associated high-risk features","volume":"12","author":"Barr CE","year":"2022","unstructured":"Barr CE, Njoku K, Jones ER, Crosbie EJ. Serum CA125 and HE4 as biomarkers for the detection of endometrial cancer and associated high-risk features. Diagnostics (Basel). 2022, 12:10.3390\/diagnostics12112834","journal-title":"Diagnostics (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.2416","article-title":"Preoperative identification of a low-risk group for lymph node metastasis in endometrial cancer: a Korean gynecologic oncology group study","volume":"30","author":"Kang S","year":"2012","unstructured":"Kang S, Kang WD, Chung HH, et al.. Preoperative identification of a low-risk group for lymph node metastasis in endometrial cancer: a Korean gynecologic oncology group study. J Clin Oncol. 2012, 30:1329-34. 10.1200\/JCO.2011.38.2416","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103851","article-title":"Advanced and recurrent endometrial cancer: state of the art and future perspectives","volume":"180","author":"Tronconi F","year":"2022","unstructured":"Tronconi F, Nero C, Giudice E, et al.. Advanced and recurrent endometrial cancer: state of the art and future perspectives. Crit Rev Oncol Hematol. 2022, 180:103851. 10.1016\/j.critrevonc.2022.103851","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001822","article-title":"Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy","volume":"31","author":"van den Heerik AS","year":"2021","unstructured":"van den Heerik AS, Horeweg N, de Boer SM, Bosse T, Creutzberg CL. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. Int J Gynecol Cancer. 2021, 31:594-604. 10.1136\/ijgc-2020-001822","journal-title":"Int J Gynecol Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/355515-mismatch-repair-deficient-figo-stage-ia-endometrial-adenocarcinoma-with-negative-nodal-biopsy-presenting-as-isolated-orbital-metastasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:39:00Z","timestamp":1745973540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/355515-mismatch-repair-deficient-figo-stage-ia-endometrial-adenocarcinoma-with-negative-nodal-biopsy-presenting-as-isolated-orbital-metastasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.83216","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}